Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Federal Trade Commission
Cipla
Chinese Patent Office
Chubb
Express Scripts
Daiichi Sankyo
Medtronic
Merck
Covington

Generated: October 19, 2017

DrugPatentWatch Database Preview

Details for Patent: 9,296,753

« Back to Dashboard

Which drugs does patent 9,296,753 protect, and when does it expire?


Patent 9,296,753 protects IMBRUVICA and is included in one NDA.

This patent has twenty-nine patent family members in twenty-five countries.

Summary for Patent: 9,296,753

Title:Crystalline forms of a Bruton's tyrosine kinase inhibitor
Abstract: Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pi- peridin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
Inventor(s): Smyth; Mark (Foster City, CA), Goldman; Erick (Concord, CA), Wirth; David D. (Oak Ridge, NC), Purro; Norbert (Los Gatos, CA)
Assignee: Pharmacyclics LLC (Sunnyvale, CA)
Application Number:13/908,949
Patent Claim Types:
see list of patent claims
Compound; Formulation; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Pharmacyclics Inc
IMBRUVICA
ibrutinib
CAPSULE;ORAL205552-001Nov 13, 2013RXYesYes► Subscribe► SubscribeYY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 9,296,753

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,540,382Crystalline forms of a Bruton's tyrosine kinase inhibitor► Subscribe
9,725,455Crystalline forms of a bruton's tyrosine kinase inhibitor► Subscribe
9,713,617Crystalline forms of a Bruton's tyrosine kinase inhibitor► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 9,296,753

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina092844► Subscribe
Australia2013271918► Subscribe
Australia2016250445► Subscribe
Canada2875986► Subscribe
Chile2014003306► Subscribe
China104736178► Subscribe
Colombia7240408► Subscribe
Costa Rica20140558► Subscribe
Dominican RepublicP2014000274► Subscribe
Dominican RepublicP2017000152► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Julphar
Chubb
Express Scripts
Baxter
Harvard Business School
Cantor Fitzgerald
UBS
AstraZeneca
Citi
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot